Cytosorbents (CTSO) Price/OCF Ratio: History & Chart

Cytosorbents Corporation(CTSO)

Medical - Devices · Princeton, NJ

$3.84-0.13 (-3.15%)

Delayed quote: Oct 6, 2026, 9:33 AM EDT

About Cytosorbents Corporation

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

Princeton, NJ

129 employees

www.cytosorbents.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Phillip Chan

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Cytosorbents Corporation (CTSO)	$12.07M	N/A	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.50M	N/A	N/A	N/A	N/A
IRIDEX Corporation (IRIX)vs ›	$12.70M	N/A	9.81	9.81	9.81
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.39M	N/A	5.31	5.31	5.31
Cerenome, Inc. (CNSY)vs ›	$11.29M	N/A	N/A	N/A	N/A
Biofrontera Inc. (BFRI)vs ›	$11.27M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.21M	N/A	6.96	6.96	6.96
BioVie Inc. (BIVI)vs ›	$11.09M	N/A	N/A	N/A	N/A
Dare Bioscience, Inc. (DARE)vs ›	$13.18M	N/A	3.83	3.83	3.83
Cellectar Biosciences, Inc. (CLRB)vs ›	$13.26M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Cytosorbents Corporation (CTSO)

$12.07M

N/A

Adial Pharmaceuticals, Inc. (ADIL)vs ›

$11.50M

N/A

IRIDEX Corporation (IRIX)vs ›

$12.70M

N/A

9.81

Lisata Therapeutics, Inc. (LSTA)vs ›

$11.39M

N/A

5.31

Cerenome, Inc. (CNSY)vs ›

$11.29M

N/A

Biofrontera Inc. (BFRI)vs ›

$11.27M

N/A

Kiora Pharmaceuticals, Inc. (KPRX)vs ›

$11.21M

N/A

6.96

BioVie Inc. (BIVI)vs ›

$11.09M

N/A

Dare Bioscience, Inc. (DARE)vs ›

$13.18M

N/A

3.83

Cellectar Biosciences, Inc. (CLRB)vs ›

$13.26M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

CTSO Price/OCF Ratio Metrics

CTSO Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics